Physician profile
Edward Shin
NPI 1427084433
$2,255.83
in general payments reported to CMS, 2019-2025
27 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $346 · 2021: $382 · 2022: $473 · 2023: $325 · 2024: $213 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $340.42 | 2021-2025 | Botox |
| Collegium Pharmaceutical, INC. | $245.56 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $185.89 | 2022 | |
| Si-Bone, INC. | $140.56 | 2019-2023 | |
| Lundbeck LLC | $136.06 | 2021-2024 | Vyepti |
| Lilly USA, LLC | $125.90 | 2019-2023 | Emgality |
| Allergan, INC. | $119.01 | 2019-2022 | |
| Boston Scientific Corporation | $105.04 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Arbor Pharmaceuticals, INC. | $88.14 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.49 | 2019-2024 | Relistor |
| Forte Bio-Pharma LLC | $82.63 | 2020 | |
| Abbott Laboratories | $73.46 | 2019 | |
| Azurity Pharmaceuticals, INC. | $64.43 | 2023-2024 | Horizant, Horizant |
| Pfizer INC. | $56.32 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $55.78 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $48.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.78 | 2019 | |
| International Rehabilitative Sciences, INC | $43.23 | 2025 | Rs-4i Plus With Intersperse |
| Medtronic Vascular, INC. | $38.22 | 2020 | |
| Valinor Pharma, LLC | $34.77 | 2023 | Movantik |
| Medtronic, INC. | $28.35 | 2022 | |
| Horizon Therapeutics Plc | $25.10 | 2020 | |
| Redhill Biopharma INC. | $21.21 | 2020 | |
| Mdd US Operations, LLC | $17.70 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.26 | 2024 | Quviviq |
| Hikma Pharmaceuticals USA | $14.31 | 2024 | Kloxxado |
| Assertio Therapeutics, INC. | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.